ReviewInternational journal of molecular sciences2016
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Breast cancer cells promote osteoclast differentiation in an MRTF-dependent paracrine manner.Molecular biology of the cell · 2025Article
- Alendronate-Grafted Nanoemulsions for Bone-Targeted Vincristine Delivery: Preliminary Studies on Cell and Animal Models.Biomolecules · 2024Article
- Review
- Review
- A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases.Cancers · 2022Review
- Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells.Cancers · 2022Article
- Imaging of metastatic epidural spinal cord compression.Frontiers in radiology · 2022Review
- Formation of pre-metastatic bone niche in prostate cancer and regulation of traditional chinese medicine.Frontiers in pharmacology · 2022Review
- A Five Collagen-Related Gene Signature to Estimate the Prognosis and Immune Microenvironment in Clear Cell Renal Cell Cancer.Vaccines · 2021Article
- Dynamic modeling of bone remodeling, osteolytic metastasis and PK/PD therapy: introducing variable order derivatives as a simplification technique.Journal of mathematical biology · 2021Review
- The Roadmap of RANKL/RANK Pathway in Cancer.Cells · 2021Review
- c-Met expression in renal cell carcinoma with bone metastases.Journal of bone oncology · 2020Review
- Bisphosphonate-based nanocomposite hydrogels for biomedical applications.Bioactive materials · 2020Review
- Article
- Review
- Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer.Oncotarget · 2020Article
- Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis.Journal of translational medicine · 2019Article
- Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.British journal of clinical pharmacology · 2019Review
- Modelling cancer outcomes of bone metastatic patients: combining survival data with N-Telopeptide of type I collagen (NTX) dynamics through joint models.BMC medical informatics and decision making · 2019Article
- Cellular and Molecular Mediators of Bone Metastatic Lesions.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastases ultimately result from a complex interaction between cancer cells and bone microenvironment. However, prior to the colonization of the bone, cancer cells must succeed through a series of steps that will allow them to detach from the primary tumor, enter into circulation, recognize and adhere to specific endothelium, and overcome dormancy. We now know that as important as the metastatic cascade, tumor cells prime the secondary organ microenvironment prior to their arrival, reflecting the existence of specific metastasis-initiating cells in the primary tumor and circulating osteotropic factors. The deep comprehension of the molecular mechanisms of bone metastases may allow the future development of specific anti-tumoral therapies, but so far the approved and effective therapies for bone metastatic disease are mostly based in bone-targeted agents, like bisphosphonates, denosumab and, for prostate cancer, radium-223. Bisphosphonates and denosumab have proven to be effective in blocking bone resorption and decreasing morbidity; furthermore, in the adjuvant setting, these agents can decrease bone relapse after breast cancer surgery in postmenopausal women. In this review, we will present and discuss some examples of applied knowledge from the bench to the bed side in the field of bone metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.